Dec 8 2009
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (“La Jolla”)
today announced that it entered into a definitive merger agreement with
Adamis Pharmaceuticals Corporation (“Adamis”) (OTCBB:
ADMP) on December 4, 2009. Upon closing, the combined company will focus
on the development and commercialization of therapeutic products for a
variety of viral diseases, including hepatitis and influenza. Adamis
recently launched a pre-filled Epinephrine syringe and is seeking to
generate near-term revenue that can be used to support development
efforts for product candidates representing larger market opportunities.
It is anticipated that the merged company will be named Adamis
Pharmaceuticals Corporation and be headquartered in San Diego,
California.
Under the terms of the merger agreement, which were unanimously approved
by the boards of directors of both Adamis and La Jolla, Adamis will be
merged with and into a wholly-owned subsidiary of La Jolla. Immediately
prior to closing, La Jolla will implement a reverse stock split; the
precise ratio of the reverse stock split will be determined in
accordance with the terms of the merger agreement and is dependent upon
La Jolla’s net cash at closing and Adamis’s stock price prior to
closing, subject to a variable discount (which in no event will such
discount yield a stock price that is less than $0.20 or greater than
$1.50). After the reverse stock split is effected, La Jolla will issue,
and Adamis stockholders will receive, one share of La Jolla common stock
for each outstanding share of Adamis stock. Currently approximately 46
million shares of Adamis common stock are outstanding. La Jolla
estimates that after the closing of the merger, La Jolla stockholders
would hold approximately 5% - 30% of the outstanding shares of the
combined company, depending on the actual net cash at closing, the
Adamis stock price and the number of Adamis shares outstanding at
closing; actual ownership percentages may be higher or lower than these
estimates. As a result of the transaction, the Adamis stockholders prior
to the transaction will acquire a controlling interest in La Jolla.
Following the closing of the merger, it is expected that the management
team and board of directors of the combined company will be appointed by
Adamis. Dennis Carlo, the Chief Executive Officer of Adamis, will serve
as the Chief Executive Officer of the combined company after the merger.
Dr. Carlo is a veteran of the pharmaceutical and biotechnology industry.
He previously served as CEO of publicly-traded Immune Response
Corporation, Vice President of Research and Development and Therapeutic
manufacturing of Hybritech Inc. prior to its acquisition by Eli Lilly &
Co., and Director of Bacterial Vaccines and Immunology at Merck &
Company. Dr. Carlo stated, “This merger is a strategic move to raise
additional capital to enable increased marketing and sales efforts in
support of our prefilled epinephrine syringe product, which we recently
launched.” Based on La Jolla’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2009, La Jolla had cash and cash equivalents
of approximately $5.8 million and liabilities of approximately $1.0
million. La Jolla estimates that it will have between $2.5 million and
$3.0 million of “net cash” at the closing of the transaction, after
accounting for all liabilities and transaction-related expenses.
Dr. Deirdre Y. Gillespie, La Jolla’s CEO, stated, “The merger will
create a new specialty pharmaceutical company focused on the development
and commercialization of therapeutic products for a variety of viral
diseases, including hepatitis and influenza. We found the Adamis
opportunity compelling given that, in addition to the prefilled
epinephrine syringe, Adamis has a pipeline including products for
allergic rhinitis, asthma, and chronic obstructive pulmonary disease. We
think Adamis is unique in that it already has a product on the market
and is expected to be profitable in the near term.”
Investors and security holders of La Jolla are urged to read the joint
proxy statement/prospectus to be included in a registration statement
filed on Form S-4 (including any amendments or supplements thereto)
regarding the merger when it becomes available because it will contain
important information about Adamis and La Jolla. La Jolla’s stockholders
will be able to obtain a copy of the joint proxy statement/prospectus,
as well as other filings containing information about Adamis and La
Jolla, without charge, at the Internet website of the Securities and
Exchange Commission (the “SEC”) (www.sec.gov).
Copies of the joint proxy statement/prospectus and Adamis’s and La
Jolla’s filings with the SEC can also be obtained, without charge, by
directing a request to Adamis Pharmaceuticals Corporation, 2658 Del Mar
Heights Road, #555, Del Mar, California 92014, Attention: Dennis Carlo,
CEO, with respect to Adamis, and by directing a request to La Jolla
Pharmaceutical Company, 4365 Executive Drive, Suite 300, San Diego,
California 92121, Attention: Deirdre Gillespie, CEO, with respect to La
Jolla.
Source: La Jolla Pharmaceutical Company